

Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- FDA issues warning letter to ImmunityBio over misleading claims about cancer drug











